Cargando…

Mucolipidosis II: first report from Saudi Arabia

BACKGROUND AND OBJECTIVES: Mucolipidosis II (MLII) is characterized by severe global developmental delay, coarse facial features, skeletal deformities, and other systemic involvement. It is caused by a deficiency in N-acetylglucosamine-1 phosphotransferase. DESIGN AND SETTINGS: This is a case series...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfadhel, Majid, AlShehhi, Wafaa, Alshaalan, Hesham, Al Balwi, Mohammed, Eyaid, Wafaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078501/
https://www.ncbi.nlm.nih.gov/pubmed/24060719
http://dx.doi.org/10.5144/0256-4947.2013.382
_version_ 1783345098393649152
author Alfadhel, Majid
AlShehhi, Wafaa
Alshaalan, Hesham
Al Balwi, Mohammed
Eyaid, Wafaa
author_facet Alfadhel, Majid
AlShehhi, Wafaa
Alshaalan, Hesham
Al Balwi, Mohammed
Eyaid, Wafaa
author_sort Alfadhel, Majid
collection PubMed
description BACKGROUND AND OBJECTIVES: Mucolipidosis II (MLII) is characterized by severe global developmental delay, coarse facial features, skeletal deformities, and other systemic involvement. It is caused by a deficiency in N-acetylglucosamine-1 phosphotransferase. DESIGN AND SETTINGS: This is a case series study conducted at King Abdulaziz Medical City in Riyadh, Saudi Arabia, between 2008–2012. PATIENTS AND METHODS: We described three unrelated Saudi children who presented with neonatal hyperparathyroidism, microcephaly, craniosynostosis, coarse facial features, cardiac involvement, and skeletal deformities. RESULTS: The MLII diagnosis was confirmed by assaying enzyme activities in fibroblasts, which showed a severe reduction in hydrolyzed substrates compared to controls, and by identifying a pathogenic homozygous GNPTAB gene mutation. One of the children died at 2 months of age due to severe pulmonary hypertension, and the other two children were still alive at 12 months and 18 months of age, respectively. Both surviving children had severe global developmental delay at 2 months of age. CONCLUSION: Clinicians should investigate any child presenting with neonatal hyperparathyroidism, craniosynostosis, skeletal deformities, and coarse facial features for MLII.
format Online
Article
Text
id pubmed-6078501
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-60785012018-09-21 Mucolipidosis II: first report from Saudi Arabia Alfadhel, Majid AlShehhi, Wafaa Alshaalan, Hesham Al Balwi, Mohammed Eyaid, Wafaa Ann Saudi Med Original Article BACKGROUND AND OBJECTIVES: Mucolipidosis II (MLII) is characterized by severe global developmental delay, coarse facial features, skeletal deformities, and other systemic involvement. It is caused by a deficiency in N-acetylglucosamine-1 phosphotransferase. DESIGN AND SETTINGS: This is a case series study conducted at King Abdulaziz Medical City in Riyadh, Saudi Arabia, between 2008–2012. PATIENTS AND METHODS: We described three unrelated Saudi children who presented with neonatal hyperparathyroidism, microcephaly, craniosynostosis, coarse facial features, cardiac involvement, and skeletal deformities. RESULTS: The MLII diagnosis was confirmed by assaying enzyme activities in fibroblasts, which showed a severe reduction in hydrolyzed substrates compared to controls, and by identifying a pathogenic homozygous GNPTAB gene mutation. One of the children died at 2 months of age due to severe pulmonary hypertension, and the other two children were still alive at 12 months and 18 months of age, respectively. Both surviving children had severe global developmental delay at 2 months of age. CONCLUSION: Clinicians should investigate any child presenting with neonatal hyperparathyroidism, craniosynostosis, skeletal deformities, and coarse facial features for MLII. King Faisal Specialist Hospital and Research Centre 2013 /pmc/articles/PMC6078501/ /pubmed/24060719 http://dx.doi.org/10.5144/0256-4947.2013.382 Text en Copyright © 2013, Annals of Saudi Medicine This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Alfadhel, Majid
AlShehhi, Wafaa
Alshaalan, Hesham
Al Balwi, Mohammed
Eyaid, Wafaa
Mucolipidosis II: first report from Saudi Arabia
title Mucolipidosis II: first report from Saudi Arabia
title_full Mucolipidosis II: first report from Saudi Arabia
title_fullStr Mucolipidosis II: first report from Saudi Arabia
title_full_unstemmed Mucolipidosis II: first report from Saudi Arabia
title_short Mucolipidosis II: first report from Saudi Arabia
title_sort mucolipidosis ii: first report from saudi arabia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078501/
https://www.ncbi.nlm.nih.gov/pubmed/24060719
http://dx.doi.org/10.5144/0256-4947.2013.382
work_keys_str_mv AT alfadhelmajid mucolipidosisiifirstreportfromsaudiarabia
AT alshehhiwafaa mucolipidosisiifirstreportfromsaudiarabia
AT alshaalanhesham mucolipidosisiifirstreportfromsaudiarabia
AT albalwimohammed mucolipidosisiifirstreportfromsaudiarabia
AT eyaidwafaa mucolipidosisiifirstreportfromsaudiarabia